NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Oncotelic Therapeutics' Nanoparticle Drug Delivery Advancements and First-in-Human Study
TL;DR
Oncotelic Therapeutics' nanoparticle delivery system offers a competitive edge by enhancing drug bioavailability and tumor targeting for more effective cancer treatments.
Oncotelic uses its Deciparticle platform to create intravenous nanoformulations that overcome absorption limits, with Sapu-003 delivering full bioavailability of Everolimus via nanoparticles.
This technology could make cancer treatments more effective and accessible, potentially improving survival rates and quality of life for patients worldwide.
Nanoparticle drug delivery, like Oncotelic's approach, may revolutionize cancer therapy as profoundly as monoclonal antibodies transformed biologics.
Found this article helpful?
Share it with your network and spread the knowledge!
Oncotelic Therapeutics focuses on applying ultra-small carrier technologies, specifically nanoparticle delivery systems, to enhance the bioavailability, precision targeting, and therapeutic performance of existing cancer therapies.
Nanocarrier-enabled formulations are viewed as potentially transformative for drug delivery, comparable to how monoclonal antibodies revolutionized biologics, due to their ability to overcome absorption and tumor-penetration limitations of conventional treatments.
The company is preparing its first-in-human study of an intravenous Everolimus (Afinitor®) nanoformulation called Sapu-003, which it codevelops through its subsidiary/partner Sapu Nano.
Sapu-003 is designed to overcome the absorption and tumor-penetration limits of conventional oral Everolimus (Afinitor®) by delivering full bioavailability via intravenous nanoparticle delivery.
The Deciparticle™ platform is Oncotelic's nanoparticle-based delivery strategy that has been advanced through its joint venture entity, though specific technical details are not provided in the content.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on developing oncology and immunotherapy products to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates.
The company is led by CEO Dr. Vuong Trieu, who has filed more than 150 patent applications and holds 39 issued U.S. patents, providing Oncotelic with a robust portfolio of inventions.
Oncotelic owns 45% of GMP Bio, a joint venture under Dr. Trieu's leadership that advances its own pipeline of drug candidates complementing Oncotelic's strategic position in oncology and rare disease therapeutics.
The latest news and updates relating to OTLC are available in the company's newsroom at https://ibn.fm/OTLC.
The full article can be viewed at https://ibn.fm/VaID8, which provides additional details about Oncotelic's nanoparticle delivery advancements.
Curated from InvestorBrandNetwork (IBN)
